FDA Approves New Nonopioid Pain Medication, Meloxicam Injection, to Combat Opioid Crisis

The FDA has approved meloxicam injection (branded as Xifyrum) for the management of moderate to severe pain in adults. Developed by Azurity Pharmaceuticals, this new medication can be used alone or in combination with other NSAIDs. The approval comes at a time when there is a strong push to reduce the reliance on opioids for pain management.

The drug is a nonopioid alternative, addressing the risk of addiction associated with traditional opioid painkillers. It is a key component of multimodal pain control, a widely endorsed strategy that uses different types of pain relievers to manage pain more effectively and with fewer side effects.

Key features of the new injection include:

Nonopioid: It provides pain relief without the risk of addiction.
Convenient Dosing: It is administered as a once-daily dose.
Rapid Administration: It can be given as a quick intravenous (IV) bolus injection over 15 seconds, which can increase efficiency in clinical settings like hospitals or surgical centers.

Despite its benefits, the medication has a delayed onset of action, meaning it is not ideal for situations where immediate pain relief is needed. As with other NSAIDs, it should be used with caution in patients with a history of cardiovascular, gastrointestinal, or renal issues.

The Role of Pharmacists in Addressing the Opioid Crisis

The article also highlights the ongoing opioid use disorder (OUD) crisis in the U.S., noting that while deaths have decreased since 2022, it remains a significant public health issue. OUD is a chronic condition characterized by compulsive opioid use that negatively impacts an individual’s life. A large percentage of patients with OUD also suffer from chronic pain, making pain management a particularly complex challenge for them.

Pharmacists play a crucial role in managing this crisis. Their accessibility and clinical knowledge make them essential partners in patient care. They contribute by:

Ensuring the safe use of medications.
Optimizing pain management plans.
Advocating for equitable, stigma-free care for patients with OUD.

The primary treatment for OUD is medication-assisted treatment (MAT), which combines pharmacological therapy with psychosocial support. Buprenorphine is a preferred medication for OUD, particularly given the widespread use of fentanyl. Effective treatment often requires a comprehensive and individualized approach to care.